Dr. Scott Gottlieb, a partner in the venture capital firm New Enterprise Associates, and Jim O’Neill, a colleague of Peter Thiel and a managing director at Mithril Capital Management, are being considered by President-elect Donald Trump to run the FDA, a transition team source said. Gottlieb may be more widely acceptable than O’Neill, said Michael Gaba, federal policy leader of the law firm Holland & Knight’s health and life sciences team.